Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.33 |
| ▸ | TK1 | P04183 | 7/20 | 0.33 |
| ▸ | TK2 | O00142 | 9/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6756343 | 0.84 | RNASE1 (0.36) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL6301637 | 0.82 | RNASE1 (0.37) | RNASE1TK1TK2 | |
| SCHEMBL6753651 | 0.78 | RNASE1 (0.35) | RNASE1TK1TK2 | |
| SCHEMBL9755149 | 0.78 | RNASE1 (0.39) | RNASE1TK1TK2 | |
| SCHEMBL8227198 | 0.75 | PYGM (0.37) | TK1TK2 | |
| SCHEMBL8197887 | 0.73 | PYGM (0.38) | TK1TK2 | |
| SCHEMBL8227200 | 0.73 | PYGM (0.35) | TK1 | |
| SCHEMBL9064864 | 0.72 | RNASE1 (0.38) | RNASE1TK1TK2 | |
| SCHEMBL7084531 | 0.72 | LMNA (0.40) | TK1TK2 | |
| SCHEMBL7973950 | 0.71 | TOP2A (0.36) | TOP2ARNASE1TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501854-A2 | ANTISENSE MODULATION OF HMGI-C EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1465905-A2 | ANTISENSE MODULATION OF MYD88 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1463746-A2 | ANTISENSE MODULATION OF MUCIN 1, TRANSMEMBRANE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1461349-A2 | ANTISENSE MODULATION OF MHC CLASS II TRANSACTIVATOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461419-A2 | ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE 3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461461-A2 | ANTISENSE MODULATION OF CD81 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461348-A2 | ANTISENSE MODULATION OF PHOSPHOLIPID SCRAMBLASE 4 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461463-A2 | ANTISENSE MODULATION OF HEMATOPOIETIC CELL PROTEIN TYROSINE KINASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1458739-A2 | ANTISENSE MODULATION OF HUMAN FXR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-22 | — | — | EP | disclosed |
| EP-1451353-A2 | ANTISENSE MODULATION OF PHOSPHOLIPASE A2 GROUP V EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003004513-A1 | ANTISENSE MODULATION OF HKR1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
| WO-2003000707-A2 | ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002097108-A2 | ANTISENSE MODULATION OF DUAL SPECIFIC PHOSPHATASE 5 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002094847-A1 | ANTISENSE MODULATION OF PTPN2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002090591-A1 | ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002090590-A1 | ANTISENSE MODULATION OF INTERLEUKIN 12 P35 SUBUNIT EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002090594-A1 | ANTISENSE MODULATION OF PHOSPHOLIPASE A2, GROUP VI (CA2+-INDEPENDENT) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002088392-A1 | ANTISENSE MODULATION OF GU PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002088393-A1 | ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-1999002167-A1 | ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-21 | — | — | WO | disclosed |